行情

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ

实时行情|Nasdaq Last Sale

14.74
-0.04
-0.27%
休市 16:00 12/06 EST
开盘
14.63
昨收
14.78
最高
15.59
最低
14.56
成交量
33.12万
成交额
--
52周最高
43.85
52周最低
9.50
市值
5.57亿
市盈率(TTM)
-10.3942
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AUTL 新闻

  • Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers at ASH 2019
  • Benzinga.11小时前
  • Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers
  • GlobeNewswire.11小时前
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.17小时前
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.17小时前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

AUTL 简况

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.
展开

Webull提供Autolus Therapeutics Ltd - ADR的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。